Potential radiopharmaceuticals for the detection of ocular melanoma |
| |
| Authors: | A. van Langevelde C. N. M. Bakker H. Boer T. A. M. Ilmer J. A. Journée-de Korver F. M. Kaspersen E. L. Noach J. A. Oosterhuis E. K. J. Pauwels |
| |
| Affiliation: | (1) Faculty of Medicine, University of Leiden, Leiden, The Netherlands;(2) University Hospital, Leiden, The Netherlands;(3) Section K, National Institute for Nuclear Physics and High-Energy Physics, Amsterdam, The Netherlands;(4) The Netherlands Ophthalmic Research Institute, Amsterdam, The Netherlands;(5) Department of Pharmacology, Sylvius Laboratories, P.O. Box 9503, 2300 RA Leiden, The Netherlands |
| |
| Abstract: | The uptake and distribution of several 4-(substituted amino)-iodoquinolines, 131I-labelled, and of 67Ga-citrate were investigated in Syrian golden hamsters with Greene melanomas. Because of its uptake in the melanoma (tumour/eye ratio 8.9), 4-(dimethylamino-ethylamino)-7-iodoquinoline (NM113) was selected for further investigations as a possible radiopharmaceutical for ocular scintigraphy when labelled with 123I. High uptake of NM113 turned out to be incidental and could not be favourably influenced by several pharmacological pretreatments. Affinity for melanin, as shown in in vitro experiments, unfavourably influences NM113 tumour-to-eye ratios. In comparison with 67Ga-citrate, the latter, with a high tumour-to-eye ratio (44.8 after 24 h) is more promising in patient studies in which NM113 123I was not. |
| |
| Keywords: | Melanoma 67Ga-citrate Iodoquinolines |
| 本文献已被 SpringerLink 等数据库收录！ |
|
